| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Lithospermic acid B (Dan Shen Suan B, Salvianolic acid B) is a naturally occuring and potent antioxidant which is water-soluble and found in Salvia extract. It has various biological activity including antioxidant effect; antiplatelet aggregation, anticoagulant, and antithrombotic effect. Lithospermic acid B is isolated from the crude extract of Salvia miltiorrhiza.
| ln Vitro |
Salvianolic acid B (SA-B) 1 and 10 μmol/L downregulated procollagen α1(I) mRNA expression to 77.0% and51.8%, respectively, and decreased cell activity TGF-β1 secretion by 63.3% and 15.6%, respectively, in comparison to the control. (P<0.05). Additionally, SA-B 1 and 10 µmol/L reduced MAPK activity by one and two times, respectively. [3] Salvianolic acid B degrades in response to temperature. Stable for 30 hours at 4°C in an aqueous solution. On the other hand, the salvianolic acid B aqueous solution immediately breaks down at 25°C, and this breakdown is accelerated at 37, 65, and 100°C. Conversely, salvianolic acid B remained stable in total phenolic acids (TPA) for thirty hours at 4, 25, and 37 degrees Celsius. [4] Salvianolic acid B can withstand 30 hours at pH 1.5, 3.0, and 5.0 in buffered phosphate saline solutions. Sal B's stability declines when the pH rises from neutral. [4]
|
|---|---|
| ln Vivo |
Salvianolic acid B (SalB) (5 mg·kg-1·h-1) can effectively ameliorate LPS-induced pulmonary microcirculation problems, including increases in leukocyte adhesion and albumin leakage. In addition, LPS can increase the wet-to-dry weight ratio of lung tissue and the levels of tumor necrosis factor α and interleukin-8 in plasma and bronchoalveolar lavage fluid, and elevate E-selectin, intercellular adhesion molecule 1, and myeloperoxidase. , MMP-2, and MMP-9, whereas it lowers the expression of AQP-1 and AQP-5 in lung tissue, all of which are decreased by SalB pretreatment [1]. SalB treatment (10 mg/kg) significantly alleviated Aβ25-35 peptide-induced memory impairment in the passive avoidance task (P<0.05). SalB therapy also reduced the number of activated microglia and astrocytes detected during the inflammatory response after delivery of Aβ25-35 peptide. Furthermore, SalB dramatically reduced the expression levels of inducible nitric oxide synthase and cyclooxygenase-2 as well as thiobarbituric acid-reactive compounds, which were elevated by administration of Aβ25-35 peptide. In addition, SalB treatment effectively reduced the Aβ25-35 peptide-induced decrease in choline acetyltransferase and brain-derived neurotrophic factor protein levels [2].
|
| References |
[1]. Antaris AL, et al. A small-molecule dye for NIR-II imaging. Nat Mater. 2016 Feb;15(2):235-42.
[2]. Antaris AL, et al. A small-molecule dye for NIR-II imaging. Nat Mater. 2016 Feb;15(2):235-42. [3]. Antaris AL, et al. A small-molecule dye for NIR-II imaging. Nat Mater. 2016 Feb;15(2):235-42. |
| Molecular Formula |
C36H30O16
|
|---|---|
| Molecular Weight |
718.62
|
| Exact Mass |
718.1534
|
| CAS # |
121521-90-2
|
| Related CAS # |
Danshensu;76822-21-4
|
| SMILES |
O=C([C@@H]1[C@@H](C2=CC=C(O)C(O)=C2)OC3=C(O)C=CC(/C=C/C(OC(C(O)=O)CC4=CC=C(O)C(O)=C4)=O)=C13)OC(C(O)=O)CC5=CC=C(O)C(O)=C5
|
| InChi Key |
SNKFFCBZYFGCQN-QUYNTYMASA-N
|
| InChi Code |
InChI=1S/C36H30O16/c37-20-6-1-16(11-24(20)41)13-27(34(45)46)50-29(44)10-5-18-3-9-23(40)33-30(18)31(32(52-33)19-4-8-22(39)26(43)15-19)36(49)51-28(35(47)48)14-17-2-7-21(38)25(42)12-17/h1-12,15,27-28,31-32,37-43H,13-14H2,(H,45,46)(H,47,48)/b10-5+/t27?,28?,31-,32+/m0/s1
|
| Chemical Name |
2-(((2S,3S)-4-((E)-3-(1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy)-3-oxoprop-1-en-1-yl)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrobenzofuran-3-carbonyl)oxy)-3-(3,4-dihydroxyphenyl)propanoic acid
|
| Synonyms |
Lithospermic acid B Dan Shen Suan B, Danfensuan B Salvianolic acid B, Salvianolic acid B, Dan Shen Suan B Salvianolic acid B
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product is not stable in solution, please use freshly prepared working solution for optimal results. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~50 mg/mL (~69.58 mM)
DMSO : ~25 mg/mL (~34.79 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.48 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.48 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 50 mg/mL (69.58 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3916 mL | 6.9578 mL | 13.9156 mL | |
| 5 mM | 0.2783 mL | 1.3916 mL | 2.7831 mL | |
| 10 mM | 0.1392 mL | 0.6958 mL | 1.3916 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA